Advisor Group Holdings, Inc. Corbus Pharmaceuticals Holdings, Inc. Transaction History

Advisor Group Holdings, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.11 - $5.46 $137 - $6,803	1,246 Added 22.78%	6,715 $0
Q3 2022 Nov 14, 2022	BUY	$0.17 - $5.31 $0 - $5	1 Added 0.02%	5,469 $1,000
Q2 2022 Aug 10, 2022	BUY	$0.21 - $0.53 $60 - $152	287 Added 5.54%	5,468 $1,000
Q1 2022 May 04, 2022	BUY	$0.32 - $0.67 $822 - $1,721	2,569 Added 98.35%	5,181 $2,000
Q3 2021 Nov 05, 2021	SELL	$1.01 - $1.82 $1,210 - $2,182	-1,199 Reduced 31.46%	2,612 $3,000
Q2 2021 Aug 02, 2021	BUY	$1.39 - $2.21 $1 - $2	1 Added 0.03%	3,811 $6,000
Q1 2021 May 13, 2021	BUY	$1.27 - $3.42 $1,143 - $3,078	900 Added 30.93%	3,810 $7,000
Q4 2020 Feb 10, 2021	SELL	$0.94 - $1.89 $3,218 - $6,471	-3,424 Reduced 54.06%	2,910 $3,000
Q3 2020 Nov 12, 2020	SELL	$1.5 - $9.38 $3,834 - $23,975	-2,556 Reduced 28.75%	6,334 $25,000
Q2 2020 Aug 14, 2020	BUY	$4.79 - $8.39 $14,729 - $25,799	3,075 Added 52.88%	8,890 $73,000
Q1 2020 May 18, 2020	BUY	$3.44 - $7.21 $20,003 - $41,926	5,815 New	5,815 $30,000

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $1.22B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.